Supplementary Tables from Urinary Metabolites of Prostanoids and Risk of Recurrent Colorectal Adenomas in the Aspirin/Folate Polyp Prevention Study (AFPPS)

Abstract

<p>Supplementary Table 1. Urinary PGE-M, PGI-M and dTxB2 by subject characteristics*, the Aspirin/Folate Polyp Prevention Study. Supplementary Table 2. Urinary PGE-M, PGI-M and dTxB2* by subject characteristics in the placebo group, the Aspirin/Folate Polyp Prevention Study. Supplementary Table 3. Urinary PGE-M, PGI-M and dTxB2 ratios by aspirin treatment group, the Aspirin/Folate Polyp Prevention Study. Supplementary Table 4 Urinary PGE-M, PGI-M and dTxB2 levels (ng/mg creatinine) by aspirin and folic acid treatment group, the Aspirin/Folate Polyp Prevention Study. Supplementary Table 5. Association of adenoma occurrence during study treatment with the ratios of urinary prostanoids, the Aspirin/Folate Polyp Prevention Study. Supplementary Table 6. Association adenoma occurrence during study treatment with urinary PGE-M, PGI-M and dTxB2 levels in the placebo group, the Aspirin/Folate Polyp Prevention Study. Supplementary Table 7. Association adenoma occurrence during study treatment with urinary PGE-M, PGI-M and dTxB2 levels in men, the Aspirin/Folate Polyp Prevention Study. Supplementary Table 8. Association adenoma occurrence during study treatment with urinary PGE-M, PGI-M and dTxB2 levels in women, the Aspirin/Folate Polyp Prevention Study.</p>